Nontypeable Haemophilus influenzae Protein E Binds Vitronectin and Is Important for Serum Resistance

Teresia Hallström, Anna M. Blom, Peter F. Zipfel and Kristian Riesbeck
J Immunol August 15, 2009, 183 (4) 2593-2601; DOI: https://doi.org/10.4049/jimmunol.0803226

Abstract

Nontypeable Haemophilus influenzae (NTHi) commonly causes local disease in the upper and lower respiratory tract and has recently been shown to interfere with both the classical and alternative pathways of complement activation. The terminal pathway of the complement system is regulated by vitronectin that is a component of both plasma and the extracellular matrix. In this study, we identify protein E (PE; 16 kDa), which is a recently characterized ubiquitous outer membrane protein, as a vitronectin-binding protein of NTHi. A PE-deficient NTHi mutant had a markedly reduced survival in serum compared with the PE-expressing isogenic NTHi wild type. Moreover, the PE-deficient mutant showed a significantly decreased binding to both soluble and immobilized vitronectin. In parallel, PE-expressing Escherichia coli bound soluble vitronectin and adhered to immobilized vitronectin compared with controls. Surface plasmon resonance technology revealed a KD of 0.4 μΜ for the interaction between recombinant PE and immobilized vitronectin. Moreover, the PE-dependent vitronectin-binding site was located at the heparin-binding domains of vitronectin and the major vitronectin-binding domain was found in the central core of PE (aa 84–108). Importantly, vitronectin bound to the surface of NTHi 3655 reduced membrane attack complex-induced hemolysis. In contrast to incubation with normal human serum, NTHi 3655 showed a reduced survival in vitronectin-depleted human serum, thus demonstrating that vitronectin mediates a protective role at the bacterial surface. Our findings show that PE, by binding vitronectin, may play an important role in NTHi pathogenesis.

The complement system is the first line of innate defense against pathogenic microorganisms. Activation of this system leads to a deposition of complement proteins on the bacterial surface, which results in opsonization of pathogens. This facilitates phagocytosis, release of chemoattractants as well as formation of the membrane attack complex (MAC).3 Formation of MAC is under control of two inhibitors, the membrane protein CD59 and the multifunctional glycoprotein vitronectin that is found both in plasma and in the extracellular matrix (ECM) (1). In human plasma, vitronectin exists in three forms, a single chain (75 kDa) and two truncated variants of 65 and 10 kDa. Vitronectin binds the C5b-7 complex at its membrane-binding site and thereby inhibits the insertion of the complex into the cell membrane. Therefore, formation of cytolytic MAC is inhibited and lysis of the cell prevented (2). In the presence of vitronectin, the C5b-7 complex is still able to bind C8 and C9 to form C5b-8 and C5b-9 complexes but the latter is nonlytic. Furthermore, vitronectin blocks pore-forming polymerization of C9 by binding C5b-9 (3, 4). Vitronectin is also involved in cell adhesion, spreading and migration, coagulation, fibrinolysis, and finally as a 75-kDa building block in the ECM (1, 2).

Haemophilus influenzae is an important human-specific pathogen that can be classified according to the presence of a polysaccharide capsule (5). The encapsulated strains cause invasive diseases, whereas the unencapsulated and hence nontypeable H. influenzae (NTHi) are mainly found in local upper and lower respiratory tract infections (6, 7). NTHi is, after Streptococcus pneumoniae, the most common cause of acute otitis media in children and is the main cause of exacerbations in patients suffering from chronic obstructive pulmonary disease and bronchiectasis (8, 9).

The pathogenesis of many microorganisms relies on their capacity to avoid, resist, or neutralize the host defense including the complement system. Therefore, many pathogens have evolved different mechanisms to avoid complement-mediated killing. Some pathogens are able to inactivate complement components, whereas others express proteins that mimic the complement inhibitors of the host (10). Another frequent strategy used by some pathogens is binding of complement inhibitors such as vitronectin, C4b-binding protein (C4BP), and factor H, which all protect from the complement-mediated attack. These inhibitors are captured on the bacterial surface in such a way that they are still functionally active. The exact mechanism of how H. influenzae evades the host complement attack is unclear. In a previous study, we showed that NTHi binds C4BP and that this interaction significantly contributes to bacterial serum resistance (11). Both H. influenzae type b (Hib) and NTHi bind surface-associated vitronectin equally well, and it has been suggested that adhesins are involved in the binding (12). We have shown in a previous study that H. influenzae surface fibrils (Hsf), which solely can be found in Hib, interacts with vitronectin and thereby prevents complement-induced lysis, resulting in increased bacterial survival in normal human serum (NHS) (13). In addition, both NTHi and encapsulated H. influenzae bind the alternative pathway inhibitor factor H, which is able to inhibit lysis of H. influenzae (14).

An initial step in the H. influenzae pathogenesis is adherence to the mucosa in the respiratory tract (15). Thereafter, adherence to the epithelial cells is a mechanism to circumvent the mucociliary clearance. Penetration of bacteria between host cells may also facilitate evasion from the immune system. Moreover, bacteria can reach the basement membrane and the ECM and may penetrate into deeper tissue layers and consequently into the circulation. In fact, H. influenzae expresses a number of surface structures that influence the process of adherence and colonization. Pili have been shown to exhibit adherence to human oropharyngeal epithelial cells, fibronectin, and other ECM proteins (16, 17). Haemophilus adhesion and penetration protein is another adhesin that has been reported to bind fibronectin, laminin, and collagen IV (18). Hsf is the major nonpilus adhesin found in encapsulated H. influenzae and this large outer membrane protein interacts with epithelial cells in addition to vitronectin (13, 19).

The recently discovered H. influenzae protein E (PE) is a low-molecular-mass (16 kDa) outer membrane lipoprotein with adhesive properties (20, 21). PE-expressing H. influenzae in addition to soluble recombinant PE(22–160) without a lipid moiety induces a proinflammatory epithelial cell response, resulting in an increased IL-8 secretion and ICAM-1 up-regulation that leads to an enhanced neutrophil adherence to epithelial cells. The adhesive PE domain is located within the central part of the molecule (aa 84–108) and preincubation of epithelial cells with this peptide blocks adhesion of several clinical NTHi isolates. In the present study, we demonstrate that H. influenzae PE binds both immobilized and soluble vitronectin and that this interaction contributes to bacterial serum resistance. Importantly, vitronectin bound to the surface of NTHi 3655 was functionally active and reduced MAC-induced hemolysis, and when NTHi 3655 was exposed to vitronectin-depleted serum a significantly decreased bacterial survival was seen.

Materials and Methods

Bacterial strains and culture conditions

The NTHi 3655 was a gift from R. Munson (The Ohio State University, Columbus, OH) (22) and the NTHi 3655Δpe mutant was previously described (21). NTHi, wild-type, and mutant were routinely cultured in brain-heart infusion liquid broth supplemented with NAD and hemin (both at 10 μg/ml) or on chocolate agar plates at 37°C in a humid atmosphere containing 5% CO2. The PE-deficient mutant was cultured in the presence of 17 μg/ml kanamycin (Merck). Escherichia coli BL21 (DE3) and DH5α were grown in Luria-Bertani liquid broth, whereas PE transformants were cultured with 50 μg/ml ampicillin (Sigma-Aldrich).

Antibodies

Rabbits were immunized i.m. with 200 μg of recombinant PE(22–160) emulsified in CFA (Difco and BD Biosciences) and boosted on days 18 and 36 with the same dose of protein in IFA. Blood was drawn 2–3 wk later. To increase the specificity, the PE antiserum was affinity purified with Sepharose-conjugated recombinant PE(22–160) (23). To ensure that the polyclonal Ab (pAb) reacted with recombinant PE, the pAb was analyzed in ELISA. PE (100 ng/well) was immobilized overnight in microtiter plates (F96 Maxisorb; Nunc-Immuno Module) and incubated with increasing concentrations of the rabbit anti-PE pAb followed by HRP-conjugated goat anti-rabbit pAb (Dakopatts). The goat anti-human vitronectin and the FITC-conjugated donkey anti-goat pAb were purchased from Serotec. The HRP-conjugated rabbit anti-goat pAb was from Dakopatts.

DNA cloning and protein expression

The full-length PE(22–160) was expressed in E. coli as described previously (21). Briefly, the PE DNA constructs were amplified by PCR introducing the restriction enzyme sites BamHI and HindIII. Genomic DNA from NTHi 772 (HI0175–HI0178) was used as template (21). The homology between PE in NTHi 772 and NTHi 3655 is >98%. The sequence coding for the signal peptide was excluded. The PCR products were cloned into both pET26+ and pET16. The resulting plasmids were transformed into E. coli DH5α and thereafter into the expressing host BL21(DE3). The constructs were verified by sequencing using the BigDye Terminator Cycle Sequencing version 3.1 Ready Reaction Kit (Applied Biosystems). To produce recombinant PE(22–160) or expressing PE on the E. coli surface, bacteria were grown to mid-log phase (OD600, 0.6–0.8) followed by 1–3.5 h of induction with 1 mM isopropyl-1-thio-β-d-galactoside. Bacteria were sonicated and the recombinant proteins were purified using columns containing a nickel resin (Novagen and VWR International) according to the manufacturers’ instructions for native conditions.

Serum bactericidal assay

NHS was prepared from pooled blood obtained from healthy volunteers with informed consent. Human serum was depleted from C7 or vitronectin by affinity chromatography using goat anti-human C7 pAb or goat anti-human vitronectin pAb coupled to a mix of protein A-Sepharose and protein G- Sepharose (GE Healthcare) overnight at 4°C. NHS was incubated with the Ab-coated Sepharose for 1 h at 4°C, followed by centrifugation to collect the depleted serum. The C7-depleted NHS was analyzed for activity in a hemolytic assay using rabbit erythrocytes. The vitronectin-depleted serum was analyzed for the presence of vitronectin and for complement activity by Western blot and hemolytic assay, respectively. The NTHi 3655 wild-type (104) and the corresponding PE-deficient mutant (104) were diluted in DGVB++ (2.5 mM veronal buffer (pH 7.3) containing 0.1% (w/v) gelatin, 1 mM MgCl2 and 0.15 mM CaCl2) and incubated in 10% NHS, 10% heat-inactivated NHS (30 min at 56°C), and increasing concentrations of NHS (5–20%) in a final volume of 100 μl at 37°C. To analyze the effect of MAC-deficient NHS or the effect of vitronectin, the NTHi 3655 was incubated with 10% C7-depleted NHS or 10% vitronectin-depleted NHS. At different time points, 10-μl aliquots were removed and spread onto chocolate agar plates. After 18 h of incubation at 37°C, CFU were determined.

Protein labeling and direct binding assay using 125I-labeled vitronectin

Vitronectin (Sigma-Aldrich) from human plasma was labeled with 0.05 mol of iodine (GE Healthcare) per mol protein using the chloramine-T method (24). The NTHi 3655 wild-type and PE-deficient mutant strains were grown in brain-heart infusion liquid broth until mid-log phase and washed in PBS-1% BSA (Sigma-Aldrich). Bacteria (2 × 107) were incubated with increasing concentrations (0.6–60 ng/ml) of 125I-labeled vitronectin at 37°C for 1 h. After incubation, the bacteria were centrifuged (10,000 × g) through a 20% sucrose column. The tubes were frozen and cut, and radioactivity in the pellet and supernatant was measured in a gamma counter. Binding was calculated as amount of bound radioactivity (pellet) vs total radioactivity (pellet plus supernatant). In the competition assay, the NTHi 3655 wild-type was preincubated with the goat anti-vitronectin pAb (5 μg/ml) or increasing concentrations of the rabbit anti-PE pAb (0–30 μl) followed by addition of 125I-labeled vitronectin.

Flow cytometry analysis

The capacity for NTHi to bind vitronectin and the PE protein expression were analyzed by flow cytometry. The NTHi 3655 strain and the PE-deficient mutant from overnight cultures were grown in broth until mid-log phase and washed once in PBS containing 2% BSA (PBS-2% BSA). Bacteria (108) were incubated with increasing concentrations of vitronectin (0.1–10 μg/ml) or NHS (0.1–10%) for 1 h at 37°C. After washings, bacteria were incubated with goat anti-vitronectin pAb for 30 min on ice, followed by incubation with the FITC-conjugated donkey anti-goat pAb. After three additional washes, bacteria were analyzed in a flow cytometer (EPICS XL-MCL; Beckman Coulter). To analyze the expression of PE, bacteria were incubated with rabbit anti-PE pAb followed by washing with PBS-2% BSA and incubation for 30 min on ice with FITC-conjugated goat anti-rabbit pAb (Dakopatts) diluted according to the manufacturer’s instructions. After additional washes, bacteria were analyzed by flow cytometry. All incubations were done in a final volume of 100 μl of PBS-2%BSA, and the washings were done with the same buffer. Secondary pAb were added separately as negative controls for each strain analyzed. PE-expressing E. coli was analyzed for PE expression and vitronectin binding as described above. In the competition assay, the NTHi 3655 wild type was incubated with increasing concentrations of heparin (Leo, Lövens Kemiske Fabrik), NaCl, PE(84–108) (PKRYARSVRQYKILNCANYHLTQVR) (Innovagen), PE(140–160) (LYNAAQIICANYGKAFSVDKK) (Innovagen), or BSA (100 μg/ml) followed by addition of 2 μg/ml vitronectin.

Binding of H. influenzae to immobilized vitronectin

Glass slides were coated with 2 μg of human plasma vitronectin or 2 μg of BSA, air dried at room temperature, and then washed twice with PBS (13). The slides were incubated with bacteria harvested at the late exponential phase (OD600 = 0.9) for 2 h at room temperature, washed twice with PBS followed by standard Gram staining.

ELISA

Microtiter plates (F96 Polysorb; Nunc-Immuno Module) were coated with peptide fragments of PE (Innovagen), full-length PE (10 μg/ml), or BSA (10 μg/ml) in 0.1 M Tris-HCl (pH 9.0) overnight at 4°C. Plates were washed with PBS-0.05% Tween 20 and blocked for 1 h at room temperature with PBS-2% BSA. After washings, vitronectin (5 μg/ml) in PBS-2% BSA was added and incubated for 1 h at room temperature. Thereafter, the plates were washed and incubated with goat anti-human vitronectin pAb for 1 h. After additional washings, HRP-conjugated rabbit anti-goat pAb was added and incubated at room temperature for 40 min. The wells were washed, developed with 20 mM tetramethylbenzidine and 0.1 M potassium citrate, and finally the absorbance was measured at 450 nm with a MRX Microplate reader (Dynatech Laboratories).

Surface plasmon resonance

The interaction between PE(22–160) or PE(84–108) and vitronectin was further analyzed using surface plasmon resonance (Biacore 2000; Biacore and GE Healthcare). The individual flow cells of a CM5 sensor chip were activated, each with 20 μl of a mixture of 0.2 M 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide and 0.05 M N-hydroxy-sulfosuccinimide at a flow rate of 5 μl/min, after which vitronectin diluted to 20 μg/ml in 10 mM sodium acetate buffer (pH 4.0) was injected over individual flow cells to reach 2000 resonance units. Not reacted groups were blocked with 20 μl of 1 M ethanolamine (pH 8.5). A negative control was prepared for each chip by activating and subsequently blocking the surface of flow cell one. The association kinetics was studied for various concentrations of purified PE(22–160) (20–1200 nM) and the synthetic peptide PE(84–108) (30–1700 nM), or the negative controls Moraxella IgD-binding protein (MID) (1000–1200) (25) and MID(1841–1868) (26) in 10 mM HEPES (pH 7.5) supplemented with 150 mM NaCl, 3 mM EDTA, and 0.005% Tween 20. Protein solutions were injected for 120 s during the association phase at a constant flow rate of 30 μl/min. The sample was injected first over the negative control surface and then over immobilized vitronectin or recombinant MID(1000–1200). Signal from the control surface was subtracted. The dissociation was followed for 120 s at the same flow rate. In all experiments, two 10-μl injections of 2 M NaCl were used to remove bound ligands during a regeneration step. The BiaEvaluation 3.0 software (Biacore) was used to analyze sensorgrams obtained. Response units obtained at the plateau of sensorgrams were plotted against concentrations of injected protein and used for calculation of equilibrium affinity constants.

Hemolytic assay

Hemolytic assays with rabbit erythrocytes were used to determine the complement activity of the C7-depleted NHS and the vitronectin-depleted NHS. Rabbit erythrocytes (2 × 108 cells/ml; Rockland and BioTrend Chemikalien) were incubated with 10% C7- or vitronectin-depleted NHS in Mg-EGTA buffer (20 mM HEPES, 144 mM NaCl, 7 mM MgCl2, and 10 mM EGTA, pH 7.4). After an incubation for 15 min at 37°C, the erythrocytes were centrifuged and the amount of lysed erythrocytes was measured at 414 nm. To analyze the MAC regulatory effect of PE-bound or NTHi 3655-bound vitronectin, hemolytic assays using sheep erythrocytes (Rockland) were performed. Sheep erythrocytes (30 μl; 2 × 108 cells/ml) were preincubated with 1 μg/ml C5b-6 (Complement Technology) in Mg-EGTA buffer for 10 min at room temperature. NTHi 3655 (108) was preincubated with vitronectin (20 μg/ml) for 45 min at 37°C, followed by extensive washings. C7 (1 μg/ml; Complement Technology), C8 (0.2 μg/ml; Complement Technology), and C9 (1 μg/ml; Complement Technology) were preincubated with or without factor H (Complement Technology) with increasing concentrations (20–100 μg/ml) of PE with or without vitronectin (50 μg/ml) or vitronectin-coated NTHi 3655 for 5 min at room temperature in a total volume of 30 μl. After preincubation, the C5b-6-coated sheep erythrocytes were added to the mixture. After 30 min at 37°C, the erythrocytes were centrifuged and the amount of lysed erythrocytes was measured at 414 nm.

Statistics

Results were assessed by Student’s t test for paired data. A value of p ≤ 0.05 was considered to be statistically significant (∗, p ≤ 0.05; ∗∗, p ≤ 0.01; ∗∗∗, p ≤ 0.001).

Results

PE is important for NTHi survival in human serum

To analyze whether the outer membrane protein PE may have a role in NTHi survival upon exposure to NHS, the wild-type strain NTHi 3655 was mutated by introduction of a kanamycin resistance gene cassette in the gene encoding for PE (21). The wild-type NTHi 3655 and the PE-deficient mutant (NTHi 3655Δpe) were thereafter tested in a serum bactericidal assay. Interestingly, the mutant devoid of PE was significantly more sensitive to NHS compared with the isogenic wild-type strain (Fig. 1⇓A). After 10 min of incubation with 10% of NHS, ∼60% of the NTHi 3655Δpe was killed compared with none of the wild type. Both the wild-type strain and the mutant were resistant to heat-inactivated serum (Fig. 1⇓B). Moreover, when a titration of the serum concentration was performed, the NTHi 3655Δpe was more sensitive to all concentrations of serum compared with the wild-type strain (Fig. 1⇓C). Thus, these experiments suggested that PE plays a significant role in NTHi serum resistance. To investigate that the terminal pathway and MAC were responsible for the killing of NTHi 3655, the survival of NTHi 3655 in C7-depleted NHS, i.e., terminal pathway-deficient serum, was analyzed. NTHi 3655 was resistant to C7-depleted NHS, suggesting that the MAC is responsible for the killing of NTHi 3655 in NHS (Fig. 1⇓D).

FIGURE 1.
FIGURE 1.

NTHi equipped with PE has a significantly better survival in human serum. NTHi 3655 and the NTHi 3655Δpe mutant were incubated with 10% NHS (A), 10% heat-inactivated serum (B), or increasing concentrations of NHS (5–20%) (C). D, NTHi 3655 survived in C7-depleted human serum. The NTHi 3655 was incubated in the presence of 10% NHS or 10% C7-depleted serum both diluted in DGVB++. At the indicated time points, bacteria were collected and spread on chocolate agar plates to allow determination of surviving bacteria. The Number of bacteria (CFU) at the initiation of the experiment was defined as 100%. The mean values from three independent experiments are shown with error bars indicating SD. ∗, p ≤ 0.05 and ∗∗, p ≤ 0.01.

PE from H. influenzae binds human vitronectin

To determine whether H. influenzae PE is important for vitronectin-binding, NTHi 3655 and the PE mutant were incubated with soluble I125-labeled vitronectin at increasing concentrations using a direct binding assay (Fig. 2⇓A). The NTHi 3655 bound vitronectin in a dose-dependent and saturable manner. In contrast, a significantly decreased vitronectin binding was observed with NTHi 3655Δpe compared with the isogenic NTHi3655 wild-type strain. However, when NTHi 3655 and the PE-deficient mutant were incubated with higher concentrations of vitronectin (1–10 μg/ml) and the binding was analyzed by flow cytometry, we found that the PE-deficient NTHi 3655Δpe mutant also bound vitronectin (Fig. 2⇓B), although to a significantly lower level than the wild type. These results suggested existence of an additional NTHi protein, which mediates bacterial vitronectin binding. Similar results were obtained by flow cytometry when NHS was used as a source of vitronectin (Fig. 2⇓C). Flow cytometry analysis with an affinity-purified anti-PE pAb confirmed that the H. influenzae PE mutant (NTHi 3655Δpe) was PE deficient (Fig. 2⇓D) (20). Moreover, a pAb against human vitronectin inhibited the binding of vitronectin to NTHi 3655 as examined in a direct binding assay (Fig. 2⇓E). To further show that PE was involved in the interaction between vitronectin and NTHi 3655, the pAb against PE was used for blocking. This Ab inhibited ∼50% of the binding (Fig. 2⇓F). Thus, PE is important for NTHi-dependent vitronectin binding, but most likely also another vitronectin-binding outer membrane protein exists.

FIGURE 2.
FIGURE 2.

PE-expressing NTHi binds vitronectin. A, The NTHi 3655 wild type (wt) bound vitronectin in a dose-dependent manner. In contrast, the NTHi 3655Δpe mutant displayed a much weaker binding to various concentrations of vitronectin in a direct binding assay. B and C, NTHi 3655 wild type bound purified vitronectin and vitronectin from NHS in a dose-dependent manner as analyzed by flow cytometry, whereas NTHi 3655Δpe displayed a reduced binding to lower concentrations of vitronectin when compared with the wild type. D, Expression of PE on the NTHi strains used in this study was determined by flow cytometry. E, An anti-vitronectin pAb inhibited the binding of 125I-labeled vitronectin to NTHi 3655. F, Anti-PE pAb inhibited ∼50% of the binding of 125I-labeled vitronectin to NTHi 3655. In A, the wild type and isogenic mutant were incubated with 125I-labeled vitronectin at increasing concentrations (0.6–60 ng/ml) and in D and E, the wild type was incubated with 125I-labeled vitronectin and anti-vitronectin pAb or anti-PE pAb. Binding was determined as percentage of bound radioactivity vs added radioactivity measured after separation of free and bound 125I-labeled vitronectin over a sucrose column. In B and C, bacteria were incubated with increasing concentrations of vitronectin (B) or increasing concentrations of NHS (C) as indicated, followed by an anti-vitronectin pAb. A FITC-conjugated anti-goat pAb was added subsequently followed by flow cytometry analysis. In D, the NTHi 3655 wild type and PE-deficient mutant were incubated with a rabbit anti-PE antiserum and finally a FITC-conjugated goat anti-rabbit antiserum. In E and F, the vitronectin binding of NTHi in the absence of Abs was defined as 100%. The mean values of three experiments are shown with error bars corresponding to SD. ∗∗, p ≤ 0.01 and ∗∗∗, p ≤ 0.001.

To further demonstrate that PE interacted with soluble vitronectin, E. coli-expressing PE at the surface was included in our study and analyzed by the direct binding assay (Fig. 3⇓A) and flow cytometry (Fig. 3⇓B). E. coli-expressing PE bound vitronectin ∼4-fold better than the E. coli control that was transformed with an empty vector (Fig. 3⇓A). When analyzed by flow cytometry, E. coli-PE bound vitronectin (10–100 μg/ml) in a dose-dependent manner, whereas a significantly decreased binding was detected in the control (Fig. 3⇓B). When flow cytometry mean fluorescence intensity values were compared, E. coli-PE bound vitronectin ∼15-fold better than the E. coli control bacteria when incubated with the highest concentration of vitronectin (100 μg/ml; Fig. 3⇓C).

FIGURE 3.
FIGURE 3.

PE expressed on the surface of E. coli binds vitronectin. A, Bacteria were incubated with 125I-labeled vitronectin. Binding was determined as percentage of bound radioactivity vs added radioactivity measured after separation of free and bound 125I-labeled vitronectin over a sucrose column. B, Bacteria were incubated with increasing concentrations of vitronectin followed by flow cytometry analysis using an anti-vitronectin pAb and a secondary FITC-conjugated anti-goat pAb. C, Typical flow cytometry profiles showing the binding of 100 μg/ml vitronectin to E. coli-PE and the E. coli control without the PE insert. The mean values of three experiments are shown in A and B. Error bars indicate SD. ∗, p ≤ 0.05; ∗∗, p ≤ 0.01; and ∗∗∗, p ≤ 0.001.

Since vitronectin has been suggested to function as a receptor for bacteria (27), attachment of bacteria to immobilized vitronectin was investigated. NTHi 3655 and the isogenic PE mutant were applied to vitronectin-coated glass slides followed by standard Gram staining. NTHi 3655 wild type adhered to the immobilized vitronectin (Fig. 4⇓A), whereas the NTHi 3655Δpe mutant barely bound (Fig. 4⇓B). To further prove that PE interacted with immobilized vitronectin, the vitronectin-binding capacity of PE-expressing E. coli was analyzed. In similarity to PE expressing H. influenzae, E. coli-PE adhered to the vitronectin-coated glass slides (Fig. 4⇓C), whereas only a few bacteria were detected when the E. coli control was analyzed (Fig. 4⇓D). Neither NTHi nor E. coli adhered to the BSA-coated glass slides that were included as a negative control (Fig. 4⇓E, NTHi, and data not shown). The number of bacteria (bacteria/low-power field) was determined by a blinded observer and 10 low-power fields were counted to calculate means, which are shown in Fig. 4⇓F. Taken together, PE is important for binding to both immobilized and soluble vitronectin as shown with PE-expressing NTHi and E. coli.

FIGURE 4.
FIGURE 4.

PE is important for adhesion to immobilized vitronectin. A, The H. influenzae wild type adhered at a high density to vitronectin-coated glass slides. B, The NTHi 3655Δpe mutant adhered poorly to vitronectin. C, E. coli expressing PE at the bacterial cell surface adhered significantly to vitronectin. D, Wild-type E. coli adhered poorly to immobilized vitronectin. E, NTHi 3655 did not bind to BSA that was included as a negative control. F, The mean values of bacteria from 10 low-power fields are shown with error bars indicating SD. Glass slides were coated with vitronectin or BSA and incubated with the bacteria. After several washes, bacteria were Gram stained. ∗∗, p ≤ 0.01 and ∗∗∗, p ≤ 0.001.

The interaction between PE and vitronectin is based upon nonionic interactions and is inhibited by heparin

The vitronectin molecule harbors several different functional regions that are involved in cell attachment, collagen, and glycosaminoglycan binding. Vitronectin contains three heparin-binding domains (1, 28). To further investigate the nature of the interaction of vitronectin to NTHi, competition experiments were performed. The NTHi 3655 wild type was preincubated with heparin at increasing concentrations (0.01–5 μg/ml) followed by addition of vitronectin (2 μg/ml) and analysis by flow cytometry. Heparin inhibited the binding of vitronectin to NTHi in a dose-dependent manner (Fig. 5⇓A). The inhibitory concentration of heparin required to reduce the binding by 50% (IC50) was 0.1 μg/ml. To test whether an enhanced ionic strength could inhibit the interaction between NTHi 3655 and vitronectin, increasing concentrations of NaCl (0.01–1 M) were added to the reaction mixture followed by analysis of vitronectin binding by flow cytometry. However, the vitronectin binding to NTHi 3655 was not based on ionic interactions since the interaction was not inhibited even at the highest NaCl (1 M) concentration (Fig. 5⇓B). BSA, that was included as a negative control, did not interfere with the binding (Fig. 5⇓C). The affinity of the interaction between PE(22–160) and vitronectin was estimated using surface plasmon resonance technology. The equilibrium affinity constant (KD) was found to be 0.4 μM (Fig. 6⇓). No interaction with vitronectin was seen upon injection of the negative controls recombinant MID(1000–1200) or MID(1841–1868) at any concentration tested (data not shown).

FIGURE 5.
FIGURE 5.

The effect of heparin and ionic strength on the binding of vitronectin to NTHi 3655. Bacteria were incubated with vitronectin (2 μg/ml) and increasing concentrations of heparin, NaCl, or BSA followed by an anti-vitronectin pAb. A, The interaction between NTHi and vitronectin is inhibited by increasing concentrations of heparin. The vitronectin binding of NTHi in the absence of heparin, NaCl, or BSA was defined as 100%. B, The interaction between NTHi and vitronectin is not based on ionic interactions. C, BSA did not affect the binding of vitronectin to NTHi 3655. A FITC-conjugated anti-goat pAb was subsequently added as a secondary layer followed by flow cytometry analysis. The mean values of three experiments are shown with error bars indicating SD. ∗∗, p ≤ 0.01; and ∗∗∗, p ≤ 0.001.

FIGURE 6.
FIGURE 6.

PE(22–160) bound vitronectin as shown by surface plasmon resonance. PE was injected at least twice at increasing concentrations (20- 1200 nM) over a CM5 chip with bound vitronectin and in parallel over a control flow cell that was used to subtract nonspecific signal. The amount of bound PE was measured in arbitrary response units (RU, inset). The response obtained for each concentration of PE at equilibrium (Req) was plotted against the concentration of PE, which allowed for estimation of the KD.

The major vitronectin binding region is located in the central part of PE (aa 84–108)

To define the vitronectin-binding domain of PE, a series of peptides (with an overlap of four amino acids) spanning the entire PE(22–160) molecule was synthesized. The PE fragments were immobilized onto microtiter plates and vitronectin-binding was quantified by ELISA. One major vitronectin-binding domain was found within amino acids PE(84–108), which is located in the middle part of the molecule (Fig. 7⇓). However, two additional vitronectin binding sites, i.e., PE(41–68) and PE(64–88), were most likely involved in the PE-dependent vitronectin binding, albeit these sequences had a lower binding capacity compared with PE(84–108). We could also detect a clear binding of PE(84–108) to vitronectin immobilized on the surface of a Biacore chip, but the nature of the obtained sensorgrams did not allow calculation of an accurate KD value (data not shown).

FIGURE 7.
FIGURE 7.

The active vitronectin-binding domain of PE is located within PE(84–108). Peptides spanning the entire PE molecule are shown. All fragments were tested for binding to vitronectin by ELISA. The peptides were coated on microtiter plates and incubated with 5 μg/ml vitronectin. Bound vitronectin was detected with a goat anti-human vitronectin pAb followed by HRP-conjugated anti-goat pAb. Results are the mean values of three experiments and error bars indicate SD. The significance values were calculated using PE(140–160) as a reference for a nonbinding fragment. ∗, p ≤ 0.05 and ∗∗∗, p ≤ 0.001.

The interaction between vitronectin and the most efficient binding domain (PE(84–108)) was further confirmed using ELISA and a competition assay. Saturated conditions of the interaction between vitronectin and PE(84–108) were first defined in the ELISA (Fig. 8⇓A). Thereafter, NTHi 3655 was incubated with vitronectin in the presence of increasing concentrations of PE(84–108) or PE(140–160) followed by flow cytometry analyses. PE(84–108) specifically inhibited the binding between NTHi 3655 and vitronectin (Fig. 8⇓B). A total of 50 μg/ml PE(84–108) was required to block the NTHi 3655-vitronectin interaction by 75%. PE(140–160) was used as a negative control and this peptide did not block the binding between NTHi 3655 and vitronectin (Fig. 8⇓B). Taken together, the interaction between PE and vitronectin was depending on the middle part of the PE molecule and was specific as revealed by the competition experiment.

FIGURE 8.
FIGURE 8.

The binding between PE(84–108) and vitronectin is specific. A, To define saturating conditions, PE(84–108) (5 μg/ml) coated in microtiter plates was incubated with increasing concentrations of vitronectin as indicated. B, Bacteria were incubated with vitronectin (2 μg/ml) and increasing concentrations of PE(84–108) or PE(140–160) as indicated followed by a goat anti-human vitronectin pAb. FITC-conjugated anti-goat pAb was subsequently added followed by flow cytometry analysis. The vitronectin binding of NTHi in the absence of competitor was defined as 100%. The mean values of three experiments are shown with error bars indicating SD. ∗, p ≤ 0.05; ∗∗, p ≤ 0.01; and ∗∗∗, p ≤ 0.001.

Vitronectin bound to the surface of NTHi 3655 is still active and able to inhibit the MAC formation

Vitronectin regulates the terminal pathway by inhibiting membrane binding of C5b-7 and therefore inhibits the MAC assembly on the cell surface and protects it from lysis (1, 2). To analyze whether vitronectin in the presence of PE still inhibits the cytolytic activity of MAC, a hemolytic assay with the purified terminal complement proteins C5b-6, C7, C8, and C9 was performed. In the fluid phase, PE-bound vitronectin inhibited the cytolytic activity of C5b-9/MAC in a concentration-dependent manner (Fig. 9⇓A). In contrast, PE(22–160) alone did not inhibit the cytolytic activity of MAC. Vitronectin, used as a positive control, blocked lysis, whereas factor H, used as a negative control, did not inhibit the lysis. Furthermore, to determine whether surface-bound vitronectin was still active and able to inhibit MAC, NTHi 3655 was preincubated with vitronectin and the capacity to inhibit MAC was analyzed in the hemolytic assay using purified terminal complement components. Vitronectin bound to the surface of NTHi 3655 reduced the cytolytic activity of MAC significantly compared with the untreated NTHi 3655 (Fig. 9⇓B), demonstrating that vitronectin was still active and regulated the terminal pathway of complement. To further confirm that NTHi-bound vitronectin had an effect on the bacterial serum resistance, bacteria were incubated in vitronectin-depleted human serum, which retained full complement activity. NTHi 3655 showed reduced survival in the vitronectin-depleted serum (Fig. 9⇓C), suggesting that an interaction with vitronectin was important for bacterial survival.

FIGURE 9.
FIGURE 9.

Vitronectin in the presence of PE(22–160) and bound to the surface of NTHi 3655 was still able to inhibit the MAC formation and increase the survival of NTHi 3655 in NHS. Increasing concentrations of PE(22–160) (A) or NTHi 3655 (B) preincubated with vitronectin were added together with C7, C8, and C9 to C5b-6-coated sheep erythrocytes. After incubation, the hemolysis of the sheep erythrocytes was measured spectrophotometrically (A414 nm). Factor H was used as a negative control. Hemolysis of sheep erythrocytes in the presence of MAC was set to 100%. C, NTHi 3655 showed a reduced survival upon growth in vitronectin-depleted human serum containing active complement. The NTHi 3655 was incubated in the presence of 10% NHS or 10% vitronectin-depleted serum both diluted in DGVB++ and spread on chocolate agar plates to allow determination of the number of surviving bacteria. After 10 min, bacteria were collected and spread on chocolate agar plates to allow determination of surviving bacteria. The number of bacteria (CFU) at the initiation of the experiment was defined as 100%. The mean values of three separate experiments are shown and error bars correspond to SD. Statistical significance of differences was calculated using Student’s t test. ∗, p ≤ 0.05 and ∗∗∗, p ≤ 0.001.

Discussion

NTHi is a frequent colonizer of the healthy upper respiratory tract and is rarely associated with invasive disease (29). However, this pathogen is one of the most common causes of exacerbations in patients that suffer from chronic obstructive pulmonary disease (30, 31, 32, 33, 34). In addition, NTHi is a frequent cause of acute otitis media in children and frequently colonizes patients with bronchiectasis (35). In this study, we describe for the first time a direct interaction between vitronectin, which is a regulator of the terminal complement pathway, and the outer membrane protein PE from NTHi. This previously unknown interaction is of importance for NTHi survival in contact with the complement system. A generally important feature for pathogens that allows them to cause disease is their ability to avoid and resist the bactericidal activity of the complement system. A pathogen having the capability to survive in human blood has the potential to spread to other sites of the body. NTHi is a pathogen that only rarely is associated with bacteremia. Hence, the binding of vitronectin most likely occurs at the mucosal surface. Reports of the presence of complement components in the respiratory tract of healthy individuals are scarce. However, several studies indicate the importance of complement in the respiratory tract during infections. During inflammation, the permeability of the mucosa increases and plasma, including complement proteins and immunoglobulins, enter the airway lumen (36, 37, 38). This process designated plasma exudation is likely the first line of the mucosal defense. In patients with chronic otitis medium with effusion, local complement activation in the middle ear mucosa has been observed, including an intense deposition of C3 (39). In addition, factor H, factor H-like protein 1, and factor H-related protein 1/2/3/4/5 are complement components found in middle ear effusions of patients with otitis media (40). Moreover, complement activity can also be detected in the ECM during inflammation (37).

Numerous microbes interact with the complement system in several ways to protect themselves from complement attacks. One efficient strategy used by several pathogens is binding of complement inhibitors, including vitronectin, factor H, factor H-like protein 1, and C4BP (41, 42). We have previously demonstrated that Hib binds vitronectin (13). This interaction contributed to serum resistance of Hib strains and was linked to Hsf protein expression. Moraxella catarrhalis ubiquitous surface protein A2 is another surface molecule that has been found to bind vitronectin and significantly contributes to serum resistance (43).

In this study, we demonstrate that NTHi devoid of PE had a markedly reduced survival in NHS compared with the wild type. The initial increase in the number of wild-type bacteria after 5 min suggests that NTHi uses NHS as a substrate for growth. Interestingly, this phenomenon has been seen before with other NTHi strains. One example is the C4BP binding strain NTHi 506 which also initially grew better after incubation with human serum (11). In parallel, in a study performed by Hood et al. (44), a similar increase in the number of bacteria was observed when low concentrations of NHS (1.25–5%) were added to a NTHi strain. In our experimental set up, upon prolonged incubation (∼40 min), the NTHi were killed by the complement system in NHS. However, even if the majority of the bacteria is sensitive to human serum, if just a few virulent bacteria survive, these might be able to multiply and initiate an infection. When bacteria were incubated in C7-depleted NHS, which is deficient in the terminal pathway, the NTHi 3655 strain survived, confirming that activation of the terminal pathway and consequently MAC formation is responsible for the killing of NTHi.

Furthermore, a direct binding assay showed that PE was important for binding of soluble vitronectin. This finding is in contrast to a previous study, in which no binding of soluble vitronectin to H. influenzae was found (12). The reason for this discrepancy is at present unclear. However, in parallel to NTHi, Hib also binds soluble vitronectin (13). In addition to the direct binding assay, flow cytometry experiments showed a significantly decreased vitronectin binding to the NTHi 3566Δpe compared with the isogenic wild type when low vitronectin concentrations were used. However, the PE-deficient NTHi bound vitronectin at higher concentrations, suggesting the presence of a second vitronectin binding protein independently of PE. Moreover, when human serum was used as a source of vitronectin, similar results were obtained.

In addition to rendering the bacteria more resistant to complement-induced lysis, the bacteria-vitronectin interaction also contributes to the attachment and invasion into host cells. The vitronectin binding of Pseudomonas aeruginosa and Neisseria gonorrhoeae is involved in attachment and internalization of the bacteria into human epithelial cells (27, 45). Since vitronectin also is a component of the ECM, binding of H. influenzae to exposed ECM components may contribute to bacterial adherence, which is an essential step in the bacterial pathogenesis. These interactions appear to contribute to the spread of bacteria through tissue barriers into secondary sites of infection. Previous studies have shown that H. influenzae can interact with ECM and reconstituted basement membranes from cultured human epithelial cells (17). Binding to ECM proteins makes the bacteria able to reach deeper tissue layers of the mucosa. We demonstrate that the H. influenzae wild-type and PE-expressing E. coli transformants both bound to immobilized vitronectin. In contrast, when PE was deleted in H. influenzae, a significantly decreased binding was observed. Thus, PE-mediated bacterial attachment to vitronectin may be an important factor in initial colonization and bacterial spread to new sites of infection.

Three heparin-binding domains of the vitronectin molecule (residues 82–137, 175–219, and 348–376) have been identified (1, 28). We found that heparin inhibited the binding between PE-expressing H. influenzae and vitronectin. However, the interaction between PE and vitronectin is not dependent on ionic interactions between amino acids. In addition to NTHi PE, Hsf from encapsulated H. influenzae has been shown to interact with vitronectin (13). Hsf also interacts with both soluble and immobilized vitronectin and this interaction is inhibited by heparin and contributes to bacterial serum resistance. Despite the fact that PE is a low molecular mass protein (16 kDa) compared with Hsf (245 kDa), it is a potent binder of vitronectin. We compared the vitronectin-binding capacity of PE and Hsf and found that these two outer membrane proteins were approximately equally efficient in vitronectin-binding capacity (T. Hallström and K. Riebeck, unpublished observation).

To define the vitronectin-binding domains in PE, peptides spanning the entire PE molecule were analyzed for vitronectin binding in ELISA. PE(84–108) displayed the highest affinity for vitronectin and showed a dose-dependent binding to vitronectin. A relatively large area of PE (aa 41–108) is involved in binding to vitronectin. However, the highest signal in the ELISA analysis was obtained with the peptide comprising PE(84–108), which includes the adhesive domain mediating attachment to epithelial cells (20, 21). PE(84–108) has been shown to have affinity for the lung carcinoma cell line A549, the conjunctival epithelial cell line Chang, and the pharynx-derived cell line Detroit. Another proof of its importance for the interaction with epithelial cells is that PE(84–108) also is able to inhibit the attachment of NTHi to the epithelial cell surface. Furthermore, in a pulmonary clearance model, mice immunized with PE(84–108) developed Abs, resulting in a significantly faster clearance upon challenge with NTHi. In the light of the ELISA results, it is suggested that two binding sites exist in the PE molecule. However, the most significant PE-dependent vitronectin-binding domain is located within aa 84–108, since it was possible to fully block the PE-vitronectin interaction with PE(84–108). Interestingly, PE(84–108) at a low concentration (2 μg/ml) increased binding of vitronectin to whole bacteria. The explanation for this is at present unclear. However, PE(84–108) at ≥10 μg/ml significantly inhibited the binding between vitronectin and NTHi. The precise binding domain of PE on the vitronectin molecule is at present unknown and is an impetus for future studies.

The formation of the lytic pore, i.e., MAC, occurs by transition of hydrophilic complement components C5b, C6, C7, and C8, resulting in polymerization of C9. Vitronectin inhibits both the assembly and formation of MAC by inhibiting the C5b-7 complex at its membrane binding site (2). The insertion of the complex into the cell membrane is thereby inhibited, preventing lysis of the microbe. Vitronectin bound to recombinant PE(22–160) and to the surface of the bacteria (NTHi 3655) maintained its inhibitory activity and inhibited lysis in a hemolytic assay. Consequently, this inactivation protects the pathogen. In addition, when bacteria were incubated in serum lacking vitronectin but with the complement system preserved, a statistically significant decrease in survival was seen with NTHi 3655. Thus, this demonstrated that binding to vitronectin protects NTHi against the attack of the complement system.

In recent years, it has been demonstrated experimentally that H. influenzae interferes with the complement system in several ways. NTHi has been shown to interact with C4BP, factor H, and factor H-like protein 1, the soluble inhibitors of the classical/lectin and alternative pathways, and thereby uses these interactions as a protection against complement-mediated attacks (11, 14). In the present study, we have identified a novel interaction between PE of NTHi and vitronectin, the regulator of the terminal pathway. PE significantly contributes to NTHi serum resistance by interacting with vitronectin, and consequently contributes to NTHi virulence. This interaction may also contribute to bacterial colonization and spread of NTHi. These observations provide an excellent background for in vivo studies using animal models to fully establish the in vivo significance of the vitronectin binding in NTHi pathogenesis.

Disclosures

The authors have no financial conflict of interest.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This work was supported by grants from the Alfred Österlund, the Anna and Edwin Berger, the Crafoord, the Marianne and Marcus Wallenberg, and the Greta and Johan Kock Foundations, the Swedish Medical Research Coucnil, the Swedish Society of Medicine, the Cancer Foundation at the University Hospital in Malmö, and the Skane County Council’s Research and Development Foundation.

  • ↵2 Address correspondence and reprint requests to Dr. Kristian Riesbeck, Medical Microbiology, Department of Laboratory Medicine, University Hospital Malmö, Lund University, SE-205 02 Malmö, Sweden. E-mail address: kristian.riesbeck{at}med.lu.se

  • ↵3 Abbreviations used in this paper: MAC, membrane attack complex; C4BP, C4b-binding protein; ECM, extracellular matrix; NTHi, nontypeable Haemophilus influenzae; Hib, H. influenzae type b; Hsf, H. influenzae surface fibril; NHS, normal human serum; OMP, outer membrane protein; pAb, polyclonal antibody; PE, protein E; MID, Moraxella IgD-binding protein.

  • Received September 26, 2008.
  • Accepted June 7, 2009.

References

  1. ↵
    Schvartz, I., D. Seger, S. Shaltiel. 1999. Vitronectin. Int. J. Biochem. Cell Biol. 31: 539-544.
    OpenUrlCrossRefPubMed
  2. ↵
    Preissner, K. T.. 1991. Structure and biological role of vitronectin. Annu. Rev. Cell Biol. 7: 275-310.
    OpenUrlCrossRefPubMed
  3. ↵
    Podack, E. R., K. T. Preissner, H. J. Muller-Eberhard. 1984. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol. Microbiol. Immunol. Scand. Suppl. 284: 89-96.
    OpenUrlPubMed
  4. ↵
    Preissner, K. T., E. R. Podack, H. J. Muller-Eberhard. 1985. The membrane attack complex of complement: relation of C7 to the metastable membrane binding site of the intermediate complex C5b-7. J. Immunol. 135: 445-451.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Kilian, M.. 2003. Haemophilus. P. R. Murray, ed. Manual of Clinical Microbology 623-635. ASM Press, Washington, DC.
  6. ↵
    Broome, C. V.. 1987. Epidemiology of Haemophilus influenzae type b infections in the United States. Pediatr. Infect. Dis. J. 6: 779-782.
    OpenUrlCrossRefPubMed
  7. ↵
    St. Geme, J. W. III.. 1993. Nontypeable Haemophilus influenzae disease: epidemiology, pathogenesis, and prospects for prevention. Infect. Agents Dis. 2: 1-16.
    OpenUrlPubMed
  8. ↵
    Cripps, A. W., D. C. Otczyk. 2006. Prospects for a vaccine against otitis media. Expert. Rev. Vaccine 5: 517-534.
    OpenUrlCrossRef
  9. ↵
    Foxwell, A. R., J. M. Kyd, A. W. Cripps. 1998. Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiol. Mol. Biol. Rev. 62: 294-308.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Kraiczy, P., R. Wurzner. 2006. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol. Immunol. 43: 31-44.
    OpenUrlCrossRefPubMed
  11. ↵
    Hallstrom, T., H. Jarva, K. Riesbeck, A. M. Blom. 2007. Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J. Immunol. 178: 6359-6366.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Eberhard, T., M. Ullberg. 2002. Interaction of vitronectin with Haemophilus influenzae. FEMS Immunol. Med. Microbiol. 34: 215-219.
    OpenUrlCrossRefPubMed
  13. ↵
    Hallstrom, T., E. Trajkovska, A. Forsgren, K. Riesbeck. 2006. Haemophilus influenzae surface fibrils contribute to serum resistance by interacting with vitronectin. J. Immunol. 177: 430-436.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Hallstrom, T., P. F. Zipfel, A. M. Blom, N. Lauer, A. Forsgren, K. Riesbeck. 2008. Haemophilus influenzae interacts with the human complement inhibitor factor H. J. Immunol. 181: 537-545.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Murphy, T. F., J. M. Bernstein, D. M. Dryja, A. A. Campagnari, M. A. Apicella. 1987. Outer membrane protein and lipooligosaccharide analysis of paired nasopharyngeal and middle ear isolates in otitis media due to nontypable Haemophilus influenzae: pathogenetic and epidemiological observations. J. Infect. Dis. 156: 723-731.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Hultgren, S. J., S. Abraham, M. Caparon, P. Falk, J. W. St. Geme, 3rd, S. Normark. 1993. Pilus and nonpilus bacterial adhesins: assembly and function in cell recognition. Cell 73: 887-901.
    OpenUrlCrossRefPubMed
  17. ↵
    Virkola, R., M. Brummer, H. Rauvala, L. van Alphen, T. K. Korhonen. 2000. Interaction of fimbriae of Haemophilus influenzae type b with heparin-binding extracellular matrix proteins. Infect. Immun. 68: 5696-5701.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Fink, D. L., B. A. Green, J. W. St. Geme, 3rd. 2002. The Haemophilus influenzae Hap autotransporter binds to fibronectin, laminin, and collagen IV. Infect. Immun. 70: 4902-4907.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    St. Geme, J. W., III, D. Cutter, S. J. Barenkamp. 1996. Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils. J. Bacteriol. 178: 6281-6287.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Ronander, E., M. Brant, E. Eriksson, M. Mörgelin, O. Hallgren, G. Westergren-Thorsson, A. Forsgren, K. Riesbeck. 2009. The non-typeable Haemophilus influenzae adhesin protein E: characterization and biological activity. J. Infect. Dis. 199: 522-531.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Ronander, E., M. Brant, H. Janson, J. Sheldon, A. Forsgren, K. Riesbeck. 2007. Identification of a novel Haemophilus influenzae protein important for adhesion to epithelial cells. Microbes Infect. 10: 87-96.
    OpenUrlPubMed
  22. ↵
    Melhus, A., A. Hermansson, A. Forsgren, K. Prellner. 1998. Intra- and interstrain differences of virulence among nontypeable Haemophilus influenzae strains. APMIS 106: 858-868.
    OpenUrlPubMed
  23. ↵
    Forsgren, A., M. Brant, A. Mollenkvist, A. Muyombwe, H. Janson, N. Woin, K. Riesbeck. 2001. Isolation and characterization of a novel IgD-binding protein from Moraxella catarrhalis. J. Immunol. 167: 2112-2120.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Greenwood, F. C., W. M. Hunter, J. S. Glover. 1963. The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem. J. 89: 114-123.
    OpenUrlPubMed
  25. ↵
    Nordstrom, T., A. Forsgren, K. Riesbeck. 2002. The immunoglobulin D-binding part of the outer membrane protein MID from Moraxella catarrhalis comprises 238 amino acids and a tetrameric structure. J. Biol. Chem. 277: 34692-34699.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Mollenkvist, A., T. Nordstrom, C. Hallden, J. J. Christensen, A. Forsgren, K. Riesbeck. 2003. The Moraxella catarrhalis immunoglobulin D-binding protein MID has conserved sequences and is regulated by a mechanism corresponding to phase variation. J. Bacteriol. 185: 2285-2295.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Leroy-Dudal, J., H. Gagniere, E. Cossard, F. Carreiras, P. Di Martino. 2004. Role of αvβ5 integrins and vitronectin in Pseudomonas aeruginosa PAK interaction with A549 respiratory cells. Microbes Infect. 6: 875-881.
    OpenUrlCrossRefPubMed
  28. ↵
    Liang, O. D., S. Rosenblatt, G. S. Chhatwal, K. T. Preissner. 1997. Identification of novel heparin-binding domains of vitronectin. FEBS Lett. 407: 169-172.
    OpenUrlCrossRefPubMed
  29. ↵
    Murphy, T.. 2001. Haemophilus infections. F. Braunwald, III, and D. Kaspar, III, and S. Hauser, III, and D. Longo, III, and L. Jameson, III, eds. Harrison’s Principles of Internal Medicine 939-942. McGraw-Hill, New York.
  30. ↵
    Bandi, V., M. A. Apicella, E. Mason, T. F. Murphy, A. Siddiqi, R. L. Atmar, S. B. Greenberg. 2001. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am. J. Resp. Crit. Care Med. 164: 2114-2119.
    OpenUrlCrossRefPubMed
  31. ↵
    Bandi, V., M. Jakubowycz, C. Kinyon, E. O. Mason, R. L. Atmar, S. B. Greenberg, T. F. Murphy. 2003. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol. Med. Microbiol. 37: 69-75.
    OpenUrlCrossRefPubMed
  32. ↵
    Groenewegen, K. H., E. F. Wouters. 2003. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir. Med. 97: 770-777.
    OpenUrlCrossRefPubMed
  33. ↵
    Patel, I. S., T. A. Seemungal, M. Wilks, S. J. Lloyd-Owen, G. C. Donaldson, J. A. Wedzicha. 2002. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57: 759-764.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Rosell, A., E. Monso, N. Soler, F. Torres, J. Angrill, G. Riise, R. Zalacain, J. Morera, A. Torres. 2005. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch. Intern. Med. 165: 891-897.
    OpenUrlCrossRefPubMed
  35. ↵
    King, P. T., J. Ngui, D. Gunawardena, P. W. Holmes, M. W. Farmer, S. R. Holdsworth. 2008. Systemic humoral immunity to non-typeable Haemophilus influenzae. Clin. Exp. Immunol. 153: 376-384.
    OpenUrlCrossRefPubMed
  36. ↵
    Greiff, L., M. Andersson, J. S. Erjefalt, C. G. Persson, P. Wollmer. 2003. Airway microvascular extravasation and luminal entry of plasma. Clin. Physiol. Funct. Imaging 23: 301-306.
    OpenUrlCrossRefPubMed
  37. ↵
    Greiff, L., I. Erjefalt, C. Svensson, P. Wollmer, U. Alkner, M. Andersson, C. G. Persson. 1993. Plasma exudation and solute absorption across the airway mucosa. Clin. Physiol. 13: 219-233.
    OpenUrlCrossRefPubMed
  38. ↵
    Persson, C. G., I. Erjefalt, U. Alkner, C. Baumgarten, L. Greiff, B. Gustafsson, A. Luts, U. Pipkorn, F. Sundler, C. Svensson, et al 1991. Plasma exudation as a first line respiratory mucosal defence. Clin. Exp. Allergy 21: 17-24.
    OpenUrlPubMed
  39. ↵
    Narkio-Makela, M., J. Jero, S. Meri. 1999. Complement activation and expression of membrane regulators in the middle ear mucosa in otitis media with effusion. Clin. Exp. Immunol. 116: 401-409.
    OpenUrlCrossRefPubMed
  40. ↵
    Narkio-Makela, M., J. Hellwage, O. Tahkokallio, S. Meri. 2001. Complement-regulator factor H and related proteins in otitis media with effusion. Clin. Immunol. 100: 118-126.
    OpenUrlCrossRefPubMed
  41. ↵
    Blom, A. M.. 2004. Strategies developed by bacteria and virus for protection from the human complement system. Scand. J. Clin. Lab. Invest. 64: 479-496.
    OpenUrlCrossRefPubMed
  42. ↵
    Zipfel, P. F., R. Wurzner, C. Skerka. 2007. Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol. Immunol. 44: 3850-3857.
    OpenUrlCrossRefPubMed
  43. ↵
    Attia, A. S., S. Ram, P. A. Rice, E. J. Hansen. 2006. Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade. Infect. Immun. 74: 1597-1611.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Hood, D. W., K. Makepeace, M. E. Deadman, R. F. Rest, P. Thibault, A. Martin, J. C. Richards, E. R. Moxon. 1999. Sialic acid in the lipopolysaccharide of Haemophilus influenzae: strain distribution, influence on serum resistance and structural characterization. Mol. Microbiol. 33: 679-692.
    OpenUrlCrossRefPubMed
  45. ↵
    Dehio, M., O. G. Gomez-Duarte, C. Dehio, T. F. Meyer. 1998. Vitronectin-dependent invasion of epithelial cells by Neisseria gonorrhoeae involves αv integrin receptors. FEBS Lett. 424: 84-88.
    OpenUrlCrossRefPubMed
View Abstract
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section